Composite Probiotic Strains for Synergistic Gout Arthritis Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for gouty arthritis are inadequate in effectively reducing pain, inflammation, and joint damage, and there is a need for a more effective probiotic intervention to manage uric acid metabolism and intestinal flora balance.
Innovation Solution
A composite probiotic formulation comprising Bifidobacterium longum BL21 strain (CGMCC No. 10452) and Lactobacillus salivarius LS97 strain (CGMCC No. 16922) is developed, which synergistically reduces pain sensitivity, leukocyte and neutrophil aggregation, myeloperoxidase activity, and inflammatory factors, while enhancing anti-inflammatory cytokines to alleviate gouty arthritis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for gouty arthritis are used, then some symptom relief may be achieved, but the effectiveness in reducing pain, inflammation, and joint damage is inadequate
Solution Approach 1:
The patent combines two probiotic strains (Bifidobacterium longum BL21 and Lactobacillus salivarius LS97) into a composite probiotic formulation. This composite approach leverages the synergistic effects of both strains to enhance uric acid metabolism regulation and anti-inflammatory properties, thereby improving treatment effectiveness for gouty arthritis while reducing pain and inflammation more effectively than single-strain probiotics or conventional treatments
2Reliability
If single-strain probiotics are used, then some improvement in uric acid metabolism may be achieved, but the overall effect on gouty arthritis is insufficient
Solution Approach 1:
The patent merges two distinct probiotic strains with complementary functions into a single formulation. Bifidobacterium longum BL21 contributes to uric acid metabolism regulation while Lactobacillus salivarius LS97 provides enhanced anti-inflammatory effects. This merging allows the probiotic intervention to address multiple aspects of gouty arthritis simultaneously, achieving comprehensive symptom relief that neither strain could achieve alone
3Quantity of substance
If conventional gout treatments are used, then some uric acid level control may be achieved, but pain sensitivity and inflammatory responses are not adequately reduced
Solution Approach 1:
The composite probiotic acts as an intermediary that addresses the root cause of gouty arthritis by regulating uric acid metabolism through intestinal flora modulation. Rather than merely controlling uric acid levels, the probiotic formulation mediates the relationship between intestinal health and uric acid metabolism, simultaneously reducing pain sensitivity and inflammatory responses through the synergistic action of both strains on multiple physiological pathways
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present application provides a compound probiotic capable of alleviating gouty arthritis and the use thereof. The compound probiotic capable of alleviating gouty arthritis consists of a Bifidobacterium longum BL21 strain and a Lactobacillus salivarius LS97 strain. The present application has discovered that the two strains can work together, mutually promote each other, and exhibit a synergistic effect in alleviating gouty arthritis. The synergistic effect is specifically demonstrated by the following: the ability to reduce pain-sensitive reactivity; the ability to decrease the number of white blood cells and the aggregation of neutrophils in joints; the ability to lower the activity of myeloperoxidase in periarticular tissues; the ability to reduce the production of the inflammatory factors CXCL1 and IL-1β; and the ability to increase the expression level of the anti-inflammatory cytokine IL-10 in joint tissues.